We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Oncology

Journal Scan / Research · September 16, 2020

Neoadjuvant Nivolumab or Nivolumab Plus Ipilimumab in Untreated Oral SCC

JAMA Oncology

 

Additional Info

JAMA Oncology
Neoadjuvant Nivolumab or Nivolumab Plus Ipilimumab in Untreated Oral Cavity Squamous Cell Carcinoma: A Phase 2 Open-Label Randomized Clinical Trial
JAMA Oncol 2020 Aug 27;[EPub Ahead of Print], JD Schoenfeld, GJ Hanna, VY Jo, B Rawal, YH Chen, PS Catalano, A Lako, Z Ciantra, JL Weirather, S Criscitiello, A Luoma, N Chau, J Lorch, JI Kass, D Annino, L Goguen, A Desai, B Ross, HJ Shah, HA Jacene, DN Margalit, RB Tishler, KW Wucherpfennig, SJ Rodig, R Uppaluri, RI Haddad

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading